Geron (NASDAQ:GERN) Stock Falls 6% – Time to Sell?

Geron Corporation (NASDAQ:GERN)’s stock price was down 6% during trading on Wednesday. The stock traded as low as $1.16 and last traded at $1.1650. Approximately 3,871,784 shares traded hands during trading, a decline of 71% from the average daily volume of 13,533,929 shares. The stock had previously closed at $1.24.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised shares of Geron from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, August 11th. Two research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Geron presently has a consensus rating of “Hold” and a consensus price target of $4.00.

Geron Price Performance

The company has a current ratio of 6.91, a quick ratio of 5.16 and a debt-to-equity ratio of 0.55. The stock has a market capitalization of $748.48 million, a price-to-earnings ratio of -10.59 and a beta of 0.61. The stock has a 50-day simple moving average of $1.37 and a 200 day simple moving average of $1.40.

Geron (NASDAQ:GERN) last announced its quarterly earnings data on Wednesday, August 5th. The biopharmaceutical company reported ($0.02) EPS for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.01). Geron had a negative net margin of 34.17% and a negative return on equity of 24.48%. The company had revenue of $57.48 million for the quarter, compared to analysts’ expectations of $55.30 million. On average, equities research analysts forecast that Geron Corporation will post -0.04 EPS for the current fiscal year.

Institutional Trading of Geron

Several large investors have recently added to or reduced their stakes in the business. LCM Capital Management Inc bought a new stake in Geron in the third quarter worth $25,000. Squarepoint Ops LLC bought a new position in Geron in the 2nd quarter worth approximately $684,000. Corient Private Wealth LP increased its position in Geron by 218.7% during the second quarter. Corient Private Wealth LP now owns 34,455 shares of the biopharmaceutical company’s stock worth $44,000 after acquiring an additional 23,643 shares during the period. Nvest Financial LLC raised its position in shares of Geron by 1.7% during the second quarter. Nvest Financial LLC now owns 517,150 shares of the biopharmaceutical company’s stock valued at $662,000 after buying an additional 8,676 shares during the last quarter. Finally, AXQ Capital LP acquired a new position in Geron in the 2nd quarter valued at approximately $122,000. 73.71% of the stock is owned by institutional investors.

About Geron

Geron Corporation (NASDAQ:GERN) is a biopharmaceutical company focused on developing and commercializing treatments for blood cancers and other serious hematologic disorders. Its lead product is Rytelo (imetelstat), a telomerase inhibitor designed to target malignant cells by interfering with telomere maintenance.

In 2024, the U.S. Food and Drug Administration approved Rytelo for adults with lower-risk myelodysplastic syndromes who require regular red blood cell transfusions and have not responded adequately to, or have lost response to, or are ineligible for, erythropoiesis-stimulating agents.